These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 9025162

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlögl E, Gisslinger H.
    Cancer; 2004 Nov 15; 101(10):2239-46. PubMed ID: 15476273
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Anagrelide: a new drug for treating thrombocytosis.
    Silverstein MN, Petitt RM, Solberg LA, Fleming JS, Knight RC, Schacter LP.
    N Engl J Med; 1988 May 19; 318(20):1292-4. PubMed ID: 3362187
    [Abstract] [Full Text] [Related]

  • 7. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
    Birgegård G, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J.
    Haematologica; 2004 May 19; 89(5):520-7. PubMed ID: 15136214
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.
    Antelo ML, de Las Heras N, Gonzalez Porras JR, Kerguelen A, Raya JM.
    Expert Rev Hematol; 2015 Dec 19; 8(6):819-35. PubMed ID: 26368319
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Role of anagrelide in the treatment of thrombocytosis.
    Brooks WG, Stanley DD, Goode JV.
    Ann Pharmacother; 1999 Oct 19; 33(10):1116-8, 1121. PubMed ID: 10534225
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness considerations in the treatment of essential thrombocythemia.
    Golub R, Adams J, Dave S, Bennett CL.
    Semin Oncol; 2002 Jun 19; 29(3 Suppl 10):28-32. PubMed ID: 12096355
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
    Silver RT.
    Leukemia; 2005 Jan 19; 19(1):39-43. PubMed ID: 15510207
    [Abstract] [Full Text] [Related]

  • 16. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.
    Am J Med; 1992 Jan 19; 92(1):69-76. PubMed ID: 1731512
    [Abstract] [Full Text] [Related]

  • 17. [Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia].
    Thiele J, Kvasnicka HM, Schmitt-Gräff A.
    Pathologe; 2002 Nov 19; 23(6):426-32. PubMed ID: 12436295
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.